In direct compression tablet manufacture for low-dose dexborneol oral solid dosage forms, blend uniformity risk is governed by the active particle size distribution and the tendency of the crystalline API to adhere to stainless steel feed frames. Development formulations have investigated dexborneol loadings of 0.5% w/w to 5.0% w/w, with the lower bound constrained by stratified content uniformity acceptance under USP <905> and the upper bound constrained by tabletability and ejection force. Dexborneol is micronized to a target D90 of 15 µm to 30 µm and pre-blended with lactose monohydrate or dibasic calcium phosphate dihydrate in a bin blender at 10–25 rpm for 15–30 min; a direct compression grade microcrystalline cellulose is added as a dry binder at 20–60% w/w. On a rotary tablet press with 10–16 stations, main compression force is held within 8–18 kN and precompression within 2–5 kN. Ejection force is monitored to remain below 300 N to avoid picking and sticking; tablet hardness is adjusted to 40–80 N, and friability is controlled to not more than 1.0% after 100 rotations under USP <1216>. Disintegration time is assessed under USP <701>, with immediate-release tablets typically disintegrating within 15 min in purified water at 37°C; dissolution is assessed under USP <711>. Magnesium stearate is added at 0.25% to 0.75% w/w, but the lipophilic surface of dexborneol may delay disintegration when total hydrophobic lubricant content exceeds 1.0% w/w. Residual solvents are controlled under ICH Q3C, with Class 3 solvents limited to 50 mg/day; elemental impurities are controlled under ICH Q3D. Manufacturing is conducted under 21 CFR 210 and 211. Finished dosage forms include uncoated tablets, film-coated tablets, and scored tablets for dose adjustment. Film coating is performed in a side-vented pan coater with inlet air temperature 55–65°C and coating suspension solids 10–15% w/w, but published data for dexborneol-specific coating temperature sensitivity are limited due to its sublimation potential.

How Does Low Aqueous Solubility Constrain Hard-Filled Capsule Dissolution?

In hard-filled capsule formulations, dexborneol is dry-blended or roller-compacted and filled into hard gelatin or HPMC capsules. Addition ratios may range from 1.0% to 8.0% w/w in a fill weight of 200–300 mg; published dexborneol-specific dissolution media data are limited. Low aqueous solubility is addressed by particle size reduction and by selecting water-soluble diluents such as lactose monohydrate or mannitol. The blend is passed through a 600 µm sieve and filled on a dosator-type encapsulator with dosing chamber diameter 5–8 mm; fill weight variation is maintained within ±3% of target and confirmed by in-process check weighing. Content uniformity is tested under USP <905>; dissolution is tested under USP <711>, with surfactant addition justified only where sink conditions are otherwise unattainable. Hard gelatin shell moisture content is controlled to 13–16% w/w, while the fill blend moisture is kept below 3.0% w/w to reduce stickiness and dexborneol migration into the shell. Encapsulation is conducted below 25°C and 40% RH to minimize volatile loss of the API. Residual solvents are controlled under ICH Q3C, and manufacturing follows 21 CFR 210 and 211. Finished product types include hard gelatin capsules, HPMC capsules for moisture-sensitive markets, and immediate-release hard capsules for oral administration.

When dexborneol is formulated as a dry suspension granule for single-dose sachet reconstitution, wet granulation is preferred over direct compression because the low dose requires geometric dilution and the final dosage form must disperse rapidly in water. Formulation addition ratio in a 1.5 g sachet fill may range from 0.1% to 2.0% w/w, corresponding to 1.5–30 mg dexborneol per dose; peer-reviewed equilibrium solubility data for dexborneol in granulation binders are limited. Dexborneol is first geometrically diluted with a water-soluble filler before loading into a high-shear granulator. Granulation is performed with a binder solution of povidone K30 at 5% w/v or hydroxypropyl methylcellulose at 3% w/v, using impeller speed 200–400 rpm and chopper speed 1500–3000 rpm for 3–6 min. The wet mass is screened through a 1.0 mm sieve and dried in a fluid-bed dryer at inlet air temperature 50–60°C; final granule moisture is controlled to 1.0–2.5% by Karl Fischer titration. Because dexborneol may sublime at elevated temperatures, the drying endpoint and product temperature are monitored to remain below 60°C. Final granule particle size is targeted at D50 150–250 µm with fines below 20% passing 75 µm to minimize segregation during sachet filling. Sachet fill weight is controlled to ±2.5% on a volumetric fill machine. Residual solvents are controlled under ICH Q3C, microbial enumeration under USP <61>, and specified microorganisms under USP <62>. Finished product types include single-dose laminated aluminum foil sachets for oral suspension, dry syrup granules for reconstitution, and granules for pediatric dose adjustment.

Injectable Solution Processing Limits and Sterile Filtration

Injectable dexborneol solutions are prepared as low-volume parenterals where the principal formulation challenge is the poor aqueous solubility of the neutral bicyclic monoterpene rather than pH-dependent ionization. Solutions are prepared at API concentrations of 0.5 mg/mL to 5.0 mg/mL using co-solvent systems containing ethanol, propylene glycol, or polyethylene glycol 400 at 10–30% v/v, or using hydroxypropyl-β-cyclodextrin at molar ratios from 1:2 to 1:5; published data for this specific formulation are limited. The solution is mixed under nitrogen blanketing to limit oxidative degradation, then passed through a 0.22 µm PVDF or PES membrane filter. Terminal moist-heat sterilization at 121°C for 15 min is not automatically applicable because dexborneol may undergo sublimation and thermal loss at sterilisation temperatures; therefore aseptic filtration followed by filling in an ISO 14644-1:2015 Class 5 zone is used for most development formulations. Particulate matter is controlled to USP <788> limits of not more than 6,000 particles per container at ≥10 µm and 600 particles per container at ≥25 µm for small-volume parenterals. Visible particulates are controlled under USP <790>. Bacterial endotoxin limits are set under USP <85> based on the maximum dose administered per kilogram per hour. Sterility is confirmed by USP <71> membrane filtration. Residual solvents are controlled under ICH Q3C, and elemental impurities under ICH Q3D. Solution pH is maintained between 4.0 and 7.0 to support container compatibility and patient tolerability. Manufacturing is performed under 21 CFR 210 and 211. Terminal finished product types include glass ampoules, vialed injectables, and pre-filled syringes with elastomeric closures.

Lyophilized Injection Cycles and Residual Moisture Specifications

Freeze-drying of dexborneol into a stable lyophilized cake requires the pre-lyophilization solution to remain physically stable through filtration and filling. Dexborneol content in the dry cake may range from 5% to 20% w/w of the total solids, with the lyoprotectant matrix at 80–95% w/w; published data for dexborneol-specific residual moisture limits are limited. The pre-lyophilization solution is filtered through a 0.22 µm membrane and filled into Type I glass vials, then loaded into a lyophilizer at a shelf temperature of −40°C. Annealing at −20°C for 2–4 h is used to promote mannitol crystallization and reduce primary drying heterogeneity. Primary drying is conducted at shelf temperatures of −20°C to −10°C under chamber pressure of 50–150 mTorr; secondary drying is conducted at 20–30°C for 6–12 h. Residual moisture is determined by Karl Fischer titration under USP <921> and is typically controlled to not more than 1.0% w/w for cakes containing mannitol, or not more than 3.0% w/w for amorphous trehalose matrices. Container closure integrity is verified by dye ingress or vacuum decay under USP <1207>. Reconstitution time is measured at 25°C with 2–5 mL of diluent; the reconstituted solution is assessed for subvisible particulate matter under USP <788> and visible particulates under USP <790>. Sterility is confirmed by USP <71>; bacterial endotoxins by USP <85>. Manufacturing follows 21 CFR 210 and 211, with aseptic operations in an ISO 14644-1:2015 Class 5 environment. Finished product types include lyophilized powder for injection in single-dose vials and dual-chamber syringe systems where the diluent is separated from the lyophilized cake.